Skip to main content

Personal wealth note: Equibles reports source-backed professional activity and disclosed compensation; it does not estimate personal net worth.

About Erin Colgan

Faeth Therapeutics, Inc. reported in an 8-K filed April 2, 2024 that Erin Colgan resigned as Chief Financial Officer, effective April 10, 2024. The proxy statement of Faeth Therapeutics, Inc. reports total compensation of $734,202 for Erin Colgan in fiscal 2023, including a base salary of $423,667. Disclosed compensation is on record for 3 fiscal years.

“On March 27, 2024, Erin Colgan notified Sensei Biotherapeutics, Inc. (the "Company") of her resignation from all positions with the Company, including as Chief Financial Officer.”
Faeth Therapeutics, Inc. Form 8-K, filed April 2, 2024 · Read the filing

Summary generated from SEC filings and earnings-call records held by Equibles.

Affiliation history

Recorded current and former roles; source labels appear when available.

Company network

Recorded roles and call appearances connecting this person to public companies.

Leadership on record at Faeth Therapeutics, Inc.

Other people whose current roles at this company are on record from its filings.

Executive compensation

Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.

Fiscal year Company Salary Total
2023 Faeth Therapeutics, Inc. (FTH) $423,667 $734,202
2022 Faeth Therapeutics, Inc. (FTH) $410,000 $855,316
2021 Faeth Therapeutics, Inc. (FTH) $317,812 $1,217,778

Recent activity

Earnings-call and investor-event appearances, plus filed executive appointments or departures, newest first.